Moderna (NASDAQ: MRNA) gave back a large piece of its historic cancer-vaccine surge on Thursday, falling about 24% to $133.32, according to on-chain data, a day after it soared 177% on the first positive Phase 3 result for an mRNA cancer vaccine. The stock steadied in Friday’s pre-market, trading slightly higher around $134. Even after the drop, Moderna is still up more than 110% on the week and over 300% for the year, so this was the market reconsidering the size of a one-day move, not unwinding the breakthrough behind it.
FinanceFeeds covered the science and the record rally when Moderna soared 177% on the cancer-vaccine breakthrough. This is what happened next, and why. The pullback is not a verdict on the data. It is the market admitting it does not yet have the one number that would justify Wednesday’s price, and that number does not arrive until late October.
Moderna spiked to about $180 on the readout, then bled back toward $133 over the next two sessions before steadying. Source: TradingViewHow Far MRNA Fell and How Far It’s Still Up
Thursday erased roughly $15.8 billion of Moderna’s market value, cutting it to about $51.5 billion, though roughly $28.7 billion of Wednesday’s gain remained. In percentage terms, about a quarter of the surge came off. The move rippled through the names that had rallied in sympathy the day before: partner Merck (NYSE: MRK) slipped about 2% and BioNTech (NASDAQ: BNTX) fell about 2% in Friday pre-market trading, giving back part of their own breakthrough-day pops.
That combination, a sharp drop that still leaves the stock enormously higher than a week ago, is the whole character of this pullback. The surge overshot, and traders who rode it took profits, but the re-rating that lifted Moderna out of its post-Covid slump has largely held.
Why the Moderna Surge Faded
Four forces pulled the stock back, and they reinforce each other. The first is simple profit-taking: a stock that nearly tripled in a session invites selling the next day. The second is that Wall Street’s own math did not keep up with the rally. The third is that the companies never disclosed how large the clinical benefit actually was.
The fourth, the most important, is captured by JPMorgan analyst Jessica Fye, who told Yahoo Finance that the melanoma win was largely expected. She wrote that with Moderna already valued near $25 billion before the news, and melanoma success already modeled at an 85% probability, the readout itself “could add ~3% to our valuation,” and that the firm sees “the read-across to other indications as critical.” In other words, melanoma alone never justified a doubling; the entire bull case rests on the platform working elsewhere.
Investor Takeaway
The most important reason for the pullback is that melanoma success was largely priced in, per JPMorgan, so the stock’s value now depends on whether the mRNA platform works in other cancers, not on the melanoma result itself.
The Targets That Are Really Warnings
Analysts responded to the data with a wave of upgrades, and yet most of their new price targets landed below where the stock was trading. Bank of America and Jefferies upgraded to Neutral with the Street-high target of $170, calling the result a “watershed moment.” But Morgan Stanley moved to just $89, Goldman to $120, RBC to $130, UBS to $150, and Citi sat at the low end at $60. The consensus settled around $85.
Even after Thursday’s drop to about $133, four of the six post-readout targets sit below the current price, and only BofA and Jefferies reached Wednesday’s close. Source: analyst notes as reported · Chart: FinanceFeedsNew targets ranged from Citi’s $60 to BofA’s $170, implying 3% to 66% downside from Wednesday’s close, and of the post-readout calls, only BofA’s $170 topped that closing price. So the upgrades were real, the science convinced Wall Street, but they doubled as a warning that the one-day move had run ahead of even the more bullish revised valuations. That is the tension FinanceFeeds laid out in its $170 bull-case, $60 bear-case breakdown, whose range brackets almost exactly where the Street landed.
The One Number Moderna Didn’t Release
The reason the targets vary so widely is that the companies gave the market a result without its magnitude. The Phase 3 announcement said the combination produced statistically significant and clinically meaningful improvements in recurrence-free and distant metastasis-free survival, but it disclosed no hazard ratio and no p-value, so the actual size of the benefit is still unknown. That single gap is why a genuine breakthrough could still leave analysts $110 apart on price.
For a reader weighing the stock, that is the honest state of play: Moderna now trades between the surge peak and the Street’s roughly $85 consensus, which means the coming data, not the last week’s tape, will settle who is right. This remains a company posting heavy losses, a $782 million net loss last quarter on revenue down 28% year over year, so the valuation already assumes years of successful execution.
What Wall Street Is Waiting For
The verdict comes at the European Society for Medical Oncology (ESMO) congress in Madrid, October 23-27, where Moderna and Merck are expected to present the full intismeran dataset. That is when the hazard ratio finally becomes public, and analysts have already set the bar: Jefferies said it expects a recurrence-free-survival hazard ratio below 0.80, with a reading below 0.70 needed to reinforce confidence, against the 0.561 seen in the earlier Phase 2 study.
A strong number would validate the surge, while a soft one would vindicate the pullback. Beyond melanoma, the platform’s nine-trial program across lung, bladder, and kidney cancers is the longer arc that determines whether this is a single win or a franchise.
Investor Takeaway
The full ESMO dataset on October 23-27 is the catalyst that matters, because it will reveal the hazard ratio the announcement withheld, and analysts have flagged below 0.70 as the level that would justify the rally.
